PT-141 for men: what the evidence shows, and what it doesn't
The short answer
PT-141 (bremelanotide) is a peptide that acts in the brain, through melanocortin receptors, rather than on the blood vessels of the penis like sildenafil or tadalafil. In men the evidence is limited to Phase 2 trials run more than a decade ago, which showed better erectile-function scores than placebo before development for ED stalled over blood-pressure concerns. Its most common side effects are nausea, flushing, and headache, and the PDE5 inhibitors remain first-line for ED.
In short: PT-141, the peptide known generically as bremelanotide, acts in the brain rather than on the blood vessels of the penis, which is what sets it apart from the pills most men know. It has been studied in men with erectile dysfunction, mostly in Phase 2 trials of a nasal spray more than a decade ago, and those trials found better erectile-function scores than placebo. Development for ED then stalled over a blood-pressure signal, and no large trial in men was completed. Below: how it works, what the male trials actually showed, how it was tested alongside sildenafil, its side effects, and how it compares with the standard first-line pills.
How does PT-141 work, and why is it different from Viagra?
PT-141 works in the brain, not in the penis, which is the main way it differs from the pills most men know. Bremelanotide is a melanocortin receptor agonist: a synthetic peptide that mimics a natural hormone and switches on melanocortin receptors, mainly MC1R and MC4R (Vyleesi via DailyMed). Signaling through these receptors in the central nervous system is thought to influence dopamine pathways involved in sexual arousal, a mechanism that is centrally acting rather than local (review of emerging ED drugs, PMC).
The standard ED medicines work the opposite way. The PDE5 inhibitors sildenafil (generic Viagra) and tadalafil (generic Cialis) act locally, relaxing the blood vessels in the penis so more blood can flow in during arousal, which our explainer on how ED medications work walks through step by step. Because PT-141 and PDE5 inhibitors act through different systems, one central and one vascular, researchers have studied whether they might work together, a point we return to below.
| Feature | PT-141 (bremelanotide) | PDE5 inhibitors (sildenafil, tadalafil) |
|---|---|---|
| Where it acts | Brain / central nervous system | Blood vessels of the penis |
| Use in men for ED | Off-label; not approved | On-label; first-line |
| How it is taken | Subcutaneous injection | Oral tablet |
| Evidence base in men | Limited Phase 2 trials; no completed Phase 3 | Large trials; decades of use |
What does the evidence for PT-141 in men actually show?
The evidence in men is limited and dated, and no Phase 3 trial program in men was ever completed. The most substantial data come from Phase 2 studies of an intranasal form of bremelanotide run more than a decade ago. In a 12-week Phase 2b trial of 726 non-diabetic men with ED, erectile-function scores were significantly higher on bremelanotide 5 mg than on placebo, and the drug also showed activity in men with diabetes and in some men who did not respond to sildenafil (review of emerging ED drugs, PMC).
That is genuinely interesting, but it is not the same as proof. These were early- and mid-stage trials, several used a nasal spray rather than the injection sold today, and development for ED did not move forward: the FDA raised significant concerns about blood-pressure increases seen in the studies, and the planned Phase 3 trials in men were delayed and never resumed (review of emerging ED drugs, PMC). No large, long-term trial has established that PT-141 is safe and effective for erectile dysfunction in men, which is why it never earned an approval for that use. Anyone presenting it as an established ED treatment for men is getting ahead of the evidence. PeptideAgent’s PT-141 profile records the same history: intranasal development for erectile dysfunction was stopped over blood pressure effects, so use in men is off-label.
Can PT-141 be combined with sildenafil?
It has been studied that way, but only in one small trial. A crossover study of 19 men found that combining low-dose intranasal PT-141 with sildenafil produced a significantly greater erectile response than sildenafil alone, and the combination was reported as well tolerated (co-administration study, PubMed). The idea behind pairing them is that the two act on different systems, one central and one vascular. A single small study is a signal worth knowing about rather than a basis for routine use, and because both drugs affect blood pressure in different ways, any combination is a question for a clinician who knows your heart history.
What are the side effects of PT-141?
The most common side effects are nausea, flushing, and headache, with two more that deserve special attention: a temporary rise in blood pressure and darkening of the skin. In the trials that supported Vyleesi’s approval in women, nausea affected about 40% of users, flushing about 20%, and headache about 11% (Vyleesi via DailyMed). The nausea can be significant, and it is a common reason people stop.
Two effects matter most for a man weighing PT-141. First, bremelanotide causes a transient increase in blood pressure and a small drop in heart rate; the peak rise in studies was modest, on the order of 6 mmHg systolic, usually returning to baseline within about 12 hours, but the drug is contraindicated in anyone with uncontrolled high blood pressure or known cardiovascular disease (Vyleesi via DailyMed). That cardiovascular signal is the same reason its development for ED stalled, and it is why this is not a casual, buy-it-online decision. Second, repeated dosing can cause focal darkening of the skin, including on the face and gums, reported in about 1% of women in the approval trials, more likely in people with darker skin or with frequent dosing, and it did not always resolve. The approved labeling also limits use to no more than one dose in 24 hours and no more than eight doses per month.
How does PT-141 compare with standard ED treatment?
For erectile dysfunction in men, the FDA-approved PDE5 inhibitors are first-line, and PT-141 is not a substitute for them. National urology guidance lists the PDE5 inhibitors, sildenafil, tadalafil, vardenafil, and avanafil, as a first-line treatment for ED (AUA Erectile Dysfunction Guideline). They are well studied, taken by mouth, and available as low-cost generics, which our guide to tadalafil versus sildenafil compares in detail, and their real-world price is covered in our breakdown of online ED treatment cost.
Safety is the other half of the comparison. PDE5 inhibitors carry one absolute rule: they must never be combined with nitrates such as nitroglycerin or isosorbide, or with the pulmonary drug riociguat, because the combination can cause a sudden, severe, and potentially fatal drop in blood pressure (sildenafil label via DailyMed). They also need careful timing with alpha-blocker blood-pressure medicines, and an erection lasting more than four hours, called priapism, is a medical emergency that needs care right away. Our rundown of ED medication side effects covers these in full. PT-141 does not share the nitrate interaction because it works through a different system, but its own blood-pressure effect is exactly why a clinician has to know your heart history before it is ever considered.
Should you consider PT-141 for ED?
If you are weighing PT-141 for ED, the honest first step is to find out why the ED is happening before reaching for any specific product. Erectile dysfunction is frequently an early sign of an underlying condition, including cardiovascular disease, diabetes, or low testosterone, so a symptom is worth investigating rather than only medicating (NIDDK, erectile dysfunction symptoms and causes). Chasing a novel injectable before that basic question is answered can mean treating the surface and missing the cause.
If low desire rather than the mechanics of an erection is your main concern, low testosterone is worth ruling out, which our sister site TRT Clarity explains in its guide to low testosterone symptoms; the link between ED and low testosterone is covered on this site too, along with the broader picture of ED and your overall health. A licensed clinician can assess whether an ED medication is appropriate for you, look for a cause, and explain where an off-label option like PT-141 might or might not fit. No legitimate service can promise a prescription or a result in advance. If you want to understand the landscape first, our overview of getting ED treatment online safely and the main guide to ED treatment online in 2026 are good places to start.
Status: FDA-approved only as Vyleesi, for premenopausal women with acquired, generalized hypoactive sexual desire disorder; the label says it is not indicated in men, so use for ED is off-label (Vyleesi prescribing information via DailyMed).
Sources
Every clinical claim on this page traces to a primary source or a clinical guideline:
- VYLEESI (bremelanotide) label via DailyMed: the approved indication (premenopausal women with acquired, generalized HSDD) and the statement that it is not indicated in men; the melanocortin receptor agonist mechanism; the common adverse reactions (nausea about 40%, flushing about 20%, headache about 11%); the transient blood-pressure increase and heart-rate decrease; the contraindication in uncontrolled hypertension or known cardiovascular disease; focal hyperpigmentation; and the dosing limits.
- The future is today: emerging drugs for the treatment of erectile dysfunction (PMC): bremelanotide’s central (CNS) mechanism via melanocortin receptors and dopamine; the 12-week Phase 2b trial in 726 non-diabetic men; activity in men with diabetes and in sildenafil non-responders; and the FDA blood-pressure concerns that delayed Phase 3 development.
- Co-administration of intranasal PT-141 and sildenafil in men with ED (PubMed): a crossover study of 19 men in which adding low-dose intranasal PT-141 to sildenafil produced a greater erectile response than sildenafil alone and was well tolerated.
- American Urological Association, Erectile Dysfunction guideline: PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) as a first-line treatment for erectile dysfunction.
- VIAGRA (sildenafil citrate) label via DailyMed: the nitrate and riociguat contraindication, the alpha-blocker caution, and the greater-than-four-hour erection (priapism) warning.
- NIH, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Erectile Dysfunction symptoms and causes: ED as a possible early sign of cardiovascular, metabolic, or hormonal disease.
This article is cited educational content, not medical or legal advice.
Advertising disclosure: links marked "Paid link" go to Bodybuilding Peptides (trybbpeptides.com), an affiliate destination, and The ED Report may earn a commission if you buy there. Our coverage is independent of that relationship, and nothing on this page is medical or legal advice.